Ezh2 inhibitors for treating lymphoma
AssigneeEpizyme, Inc.
InventorsHeike KEILHACK, Sarah Kathleen KNUTSON, Danielle Johnston BLACKWELL
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Claims26
A method for treating a germinal center-derived lymphoma in a subject in need thereof comprising administering a therapeutically effective amount of an EZH2 inhibitor.
5-6. (canceled)
10-13. (canceled)
17-18. (canceled)
A method for treating Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in a subject in need thereof comprising a step of administering a therapeutically effective amount of an EZH2 inhibitor.
20-23. (canceled)
27-30. (canceled)
34-35. (canceled)
Dependencies are inferred from the claim text.